Loading stock data…
GLSI
$22.23+0.58 (+2.68%)
Market ClosedLast close Jun 9
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Greenwich LifeSciences, Inc. in the Healthcare sector is trading at $22.23 with a market capitalization of $326M. Wall Street consensus targets $47.50 (2 analysts), implying a +113.7% move over the next 12 months. The stock is currently 35% below its 52-week high of $34.10, remaining 18.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +113.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$22.23
Potential Downside
0%
Whystock Fair Value$22.23
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$47.50+113.7%
Range$45.00 – $50.00
Fundamentals
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunother...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$326.30M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.38
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-412.83%
Volume
Today's trading volume
85,350
Recent News
GLSI Stock Climbs After Removing A Key Overhang – Retail Turns Focus To High-Stakes Breast Cancer Trial
Greenwich LifeSciences said the delay in filing Form 10-K was due to accounting adjustments tied to stronger-than-expected patient enrollment in its Phase III trial to treat breast cancer.
Insiders of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) must be frustrated after market cap dropped US$50m since recent purchases
Key Insights Insiders appear to have a vested interest in Greenwich LifeSciences' growth, as seen by their sizeable...
Sector Update: Health Care Stocks Mixed Late Afternoon
Health care stocks were mixed late Thursday afternoon, with the NYSE Health Care Index up 0.2% and t
Top Midday Gainers
60 Degrees Pharmaceuticals (SXTP) reported Thursday a partnership with Runway Health to boost access
Wall Street Set to Open Higher Thursday as Investors Parse GDP, Unemployment Data, Look Ahead to Inflation Report
US stocks look set to open higher in Thursday's trading session as investors parse gross domestic pr